Skip to Main Content

Author Details

Emanuel F Petricoin
Center for Applied Proteomics and Molecular Medicine, George Mason University
1988
463
86
Antoine Forget (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36797347AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers.NPJ Precis Oncol2023
37280243Establishment and characterization of patient-derived xenograft of a rare pediatric anaplastic pleomorphic xanthoastrocytoma (PXA) bearing a CDC42SE2-BRAF fusion.Sci Rep2023
37210417Phase II trial of fulvestrant plus enzalutamide in ER+/HER2- advanced breast cancer.NPJ Breast Cancer2023
36577061Inhibiting androgen receptor splice variants with cysteine-selective irreversible covalent inhibitors to treat prostate cancer.Proc Natl Acad Sci U S A2023
37255276Integration of Multi-omic Data in a Molecular Tumor Board Reveals EGFR-Associated ALK-Inhibitor Resistance in a Patient With Inflammatory Myofibroblastic Cancer.Oncologist2023
36548343A Single-Arm Phase II Trial of Sitravatinib in Advanced Well-Differentiated/Dedifferentiated Liposarcoma.Clin Cancer Res2023
36797347AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers.NPJ Precis Oncol2023
37255276Integration of Multi-omic Data in a Molecular Tumor Board Reveals EGFR-Associated ALK-Inhibitor Resistance in a Patient With Inflammatory Myofibroblastic Cancer.Oncologist2023
37280243Establishment and characterization of patient-derived xenograft of a rare pediatric anaplastic pleomorphic xanthoastrocytoma (PXA) bearing a CDC42SE2-BRAF fusion.Sci Rep2023
37210417Phase II trial of fulvestrant plus enzalutamide in ER+/HER2- advanced breast cancer.NPJ Breast Cancer2023
36548343A Single-Arm Phase II Trial of Sitravatinib in Advanced Well-Differentiated/Dedifferentiated Liposarcoma.Clin Cancer Res2023
36577061Inhibiting androgen receptor splice variants with cysteine-selective irreversible covalent inhibitors to treat prostate cancer.Proc Natl Acad Sci U S A2023
34635507Regulation of Chemosensitivity in Human Medulloblastoma Cells by p53 and the PI3 Kinase Signaling Pathway.Mol Cancer Res2022
36046628Analysis of neuroendocrine clones in NSCLCs using an immuno-guided laser-capture microdissection-based approach.Cell Rep Methods2022
35944066Functional and biological heterogeneity of KRAS<sup>Q61</sup> mutations.Sci Signal2022
35623341Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.Cancer Cell2022
36069770Genetically manipulating endogenous Kras levels and oncogenic mutations in vivo influences tissue patterning of murine tumorigenesis.Elife2022
35668193P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia.Nat Cancer2022
36389181Synthesis of 2-Oxoquinoline Derivatives as Dual Pim and mTORC Protein Kinase Inhibitors.Med Chem Res2022
36384096Proteogenomic analysis of lung adenocarcinoma reveals tumor heterogeneity, survival determinants, and therapeutically relevant pathways.Cell Rep Med2022
36582793Editorial: Recent advancements in neoadjuvant chemotherapy for specific breast cancer subtypes.Front Oncol2022
36494881Computational modeling of first responders' willingness to accept radiation exposure during radiological or nuclear events.Am J Disaster Med2022
36612255Integrative Multi-OMICs Identifies Therapeutic Response Biomarkers and Confirms Fidelity of Clinically Annotated, Serially Passaged Patient-Derived Xenografts Established from Primary and Metastatic Pediatric and AYA Solid Tumors.Cancers (Basel)2022
36456573Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.NPJ Breast Cancer2022
34921013Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors.Cancer Res2022
35247914Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma.Mol Cancer Ther2022
34907082Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer.Clin Cancer Res2022
35229082Development of a hybrid alphavirus-SARS-CoV-2 pseudovirion for rapid quantification of neutralization antibodies and antiviral drugs.Cell Rep Methods2022
34437759Multi-omic molecular profiling guide's efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial.Mol Oncol2022
35241721Radiotherapy alters expression of molecular targets in prostate cancer in a fractionation- and time-dependent manner.Sci Rep2022
34635507Regulation of Chemosensitivity in Human Medulloblastoma Cells by p53 and the PI3 Kinase Signaling Pathway.Mol Cancer Res2022
35668193P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia.Nat Cancer2022
35623341Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.Cancer Cell2022
36582793Editorial: Recent advancements in neoadjuvant chemotherapy for specific breast cancer subtypes.Front Oncol2022
36612255Integrative Multi-OMICs Identifies Therapeutic Response Biomarkers and Confirms Fidelity of Clinically Annotated, Serially Passaged Patient-Derived Xenografts Established from Primary and Metastatic Pediatric and AYA Solid Tumors.Cancers (Basel)2022
36494881Computational modeling of first responders' willingness to accept radiation exposure during radiological or nuclear events.Am J Disaster Med2022
36456573Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.NPJ Breast Cancer2022
36046628Analysis of neuroendocrine clones in NSCLCs using an immuno-guided laser-capture microdissection-based approach.Cell Rep Methods2022
36069770Genetically manipulating endogenous Kras levels and oncogenic mutations in vivo influences tissue patterning of murine tumorigenesis.Elife2022
36384096Proteogenomic analysis of lung adenocarcinoma reveals tumor heterogeneity, survival determinants, and therapeutically relevant pathways.Cell Rep Med2022
36389181Synthesis of 2-Oxoquinoline Derivatives as Dual Pim and mTORC Protein Kinase Inhibitors.Med Chem Res2022
35944066Functional and biological heterogeneity of KRAS<sup>Q61</sup> mutations.Sci Signal2022
34921013Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors.Cancer Res2022
35247914Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma.Mol Cancer Ther2022
34907082Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer.Clin Cancer Res2022
35241721Radiotherapy alters expression of molecular targets in prostate cancer in a fractionation- and time-dependent manner.Sci Rep2022
35229082Development of a hybrid alphavirus-SARS-CoV-2 pseudovirion for rapid quantification of neutralization antibodies and antiviral drugs.Cell Rep Methods2022
34437759Multi-omic molecular profiling guide's efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial.Mol Oncol2022
33320980Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up-regulation.Mol Oncol2021
33858214Immunoglobulin A Autoreactivity toward Brain Enriched and Apoptosis-Regulating Proteins in Saliva of Athletes after Acute Concussion and Subconcussive Impacts.J Neurotrauma2021
  • 1 - 50 of 926

Recommended Authors

Andrew Macklin
Margaret Cancer Center
Career Start Year 2016
Number of shared co-authors 3
Fabian Coscia
Max-Delbruck-Center for Molecular Medicine in the Helmholtz Association (MDC)
Career Start Year 2011
Number of shared co-authors 1
Seong Beom Ahn
Macquarie Medical School, Macquarie University
Career Start Year 2011
Number of shared co-authors 9
Ankit Sinha
Max Planck Institute of Biochemistry
Career Start Year 2011
Number of shared co-authors 2
Vladimir Ignatchenko
Margaret Cancer Center
Career Start Year 2009
Number of shared co-authors 3
Sungyong You
Cedars-Sinai Medical Center
Career Start Year 2008
Number of shared co-authors 3
Qing Zhang
Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
Career Start Year 2006
Number of shared co-authors 8
Bing Zhang
Baylor College of Medicine
Career Start Year 2005
Number of shared co-authors 16
Alex Ignatchenko
European Bioinformatics Institute (EMBL-EBI)
Career Start Year 2005
Number of shared co-authors 3
Sharon J Pitteri
Stanford University
Career Start Year 2003
Number of shared co-authors 14
Tamar Geiger
Tel Aviv University
Career Start Year 2000
Number of shared co-authors 4
Marina A Gritsenko
Pacific Northwest National Laboratory
Career Start Year 2000
Number of shared co-authors 10
Emily S Boja
Office of Cancer Clinical Proteomics Research, National Cancer Institute
Career Start Year 2000
Number of shared co-authors 17
Parag Mallick
Stanford University
Career Start Year 2000
Number of shared co-authors 13
Tao Liu
Pacific Northwest National Laboratory
Career Start Year 1998
Number of shared co-authors 15
Janne Lehti??
Karolinska Institutet
Career Start Year 1997
Number of shared co-authors 5
Thomas Kislinger
Princess Margaret Cancer Centre, University Health Network, University of Toronto
Career Start Year 1997
Number of shared co-authors 9
Julius O Nyalwidhe
Eastern Virginia Medical School
Career Start Year 1997
Number of shared co-authors 2
Mu Wang
Academy of Pharmacy, Xi'an Jiaotong-Liverpool University
Career Start Year 1996
Number of shared co-authors 3
Robert Kim
University of California
Career Start Year 1996
Number of shared co-authors 2
Forest M White
Massachusetts Institute of Technology
Career Start Year 1995
Number of shared co-authors 13
Tara Hiltke
Office of Cancer Clinical Proteomics Research, National Cancer Institute
Career Start Year 1994
Number of shared co-authors 14
Keith A Baggerly
The University of Texas MD Anderson Cancer Center
Career Start Year 1991
Number of shared co-authors 19
Fredrik Pont??n
Uppsala University
Career Start Year 1991
Number of shared co-authors 10
Kevin R Coombes
Medical College of Georgia
Career Start Year 1990
Number of shared co-authors 11
Katherine Stemke-Hale
MD Anderson Cancer Center, University of Texas
Career Start Year 1989
Number of shared co-authors 9
Stephen R Pennington
UCD Conway Institute, University College Dublin
Career Start Year 1985
Number of shared co-authors 11
Gy??rgy Marko-Varga
Clinical Protein Science & Imaging, Biomedical Centre, Lund University
Career Start Year 1984
Number of shared co-authors 16
Karin D Rodland
Oregon Health and Science University
Career Start Year 1973
Number of shared co-authors 15
Edouard C Nice
Monash University
Career Start Year 1971
Number of shared co-authors 16

Collaborators

Lance A Liotta
Co-authored papers 262
Mariaelena Pierobon
Center for Applied Proteomics and Molecular Medicine, George Mason University
Co-authored papers 62
Thomas P Conrads
Women's Health Integrated Research Center, Inova Health System
Co-authored papers 21
Michael R Emmert-Buck
The Francis Crick Institute
Co-authored papers 18
Subha Madhavan
Innovation Center for Biomedical Informatics, Georgetown University Medical Center
Co-authored papers 11
William Marston Linehan
Co-authored papers 10
Christina Yau
University of California San Francisco
Co-authored papers 9
Donald J Johann
Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences
Co-authored papers 9
Laura J Van't Veer
University of California San Francisco
Co-authored papers 9
Michael David
Co-authored papers 9
Denise M Wolf
University of California San Francisco
Co-authored papers 9
Edik M Blais
University of Virginia
Co-authored papers 9
Donald A Berry
MD Anderson Cancer Center
Co-authored papers 8
Elisa Pin
KTH Royal Institute of Technology
Co-authored papers 8
Gordon Whiteley
Co-authored papers 8
William F Symmans
Co-authored papers 8
Mark S Lowenthal
Co-authored papers 6
Mark Raffeld
Center for Cancer Research, National Cancer Institute
Co-authored papers 6
Yingming Zhao
Co-authored papers 6
Claudine Isaacs
Co-authored papers 6
Stefan Bekiranov
University of Virginia
Co-authored papers 6
Jae K Lee
Co-authored papers 5
Rita Nanda
Co-authored papers 5
John N Weinstein
The University of Texas MD Anderson Cancer Center
Co-authored papers 5
Seth M Steinberg
Center for Cancer Research, National Cancer Institute
Co-authored papers 5
Ancha Baranova
Co-authored papers 5
Judy C Boughey
Mayo Clinic
Co-authored papers 5
Paul H Duray
National Cancer Institute, National Institutes of Health
Co-authored papers 5
Peter J Munson
and Blood Institute, National Institutes of Health
Co-authored papers 5
John D Carpten
Co-authored papers 5
Release 1.2